Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
WO45654 (Inavo123)
Breast Cancer Phase III
- 8.2 weeks
- 1st site activated in Canada
WO45654 (Inavo123)
Breast Cancer Phase III
- 9 weeks
WO45654 (Inavo123)
Breast Cancer Phase III
- 11 weeks
WP45335
Hematology – Von Willebrand Disease Phase Non-Interventional
- 15.2 weeks
WP45338
Hematology - Von Willebrand Disease Phase III
- 13.6 weeks
- 1st site activated in Canada
1479-0009
Solid Tumors Phase II
- 10.8 weeks
- 1st site activated in Canada
1479-0009
Solid Tumors Phase II
- 10 weeks
- 3rd site activated in Canada
20230153
Non-Small Cell Cancer (NSCLC) Phase II
- 8 weeks
- 1st site activated in Canada
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 12.4 weeks
- 1st site activated in Canada and 2nd site activated worldwide
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 10.6 weeks
- 2nd site activated in Canada
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 4.4 weeks
AIRCULES
Asthma Phase II
- 6.8 weeks
- 2nd site activated in Canada
Airlympus
Asthma Phase II
- 6.6 weeks
- Canadian FPI - 3rd patient enrolled globally
Airlympus
Asthma Phase II
- 6.8 weeks
B-Focus
HIV / Hepatitis B Phase II
- 8.8 weeks
- 1st site activated (ex æquo) in Canada, 3rd site activated (ex æquo) worldwide, Canadian FPI
B-Focus
HIV / Hepatitis B Phase II
- 8 weeks
- 3rd site activated (ex æquo) in Canada
B-United (218309)
Chronic Hepatitis B Phase II
- 9 weeks
- 1st site activated in Canada and Canadian FPI
C1071032
Multiple Myeloma Phase III
- 14.8 weeks
- 1st site activated in Canada
CA231-0000
Advanced Malignant Tumors Phase I/Ib
- 7.2 weeks
- 1st site activated in Canada and Canadian FPI